This Week in Cardiology — Oct 5, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning the cardiovascular-kidney-metabolic continuum, acute triage, surgery and transplant surveillance, and a cluster of major guidance documents that reset everyday practice. Let's dive in.

We start with cardiovascular-kidney-metabolic disease, which several journals this week treat as the core framework for heart failure. In JAMA Cardiology, Kittipibul and colleagues used the Get With The Guidelines Heart Failure registry to examine more than 725,000 patients hospitalized for heart failure at United States hospitals [1]. Nearly three quarters of these patients had two or more additional conditions among atherosclerotic disease, chronic kidney disease, diabetes and obesity, and only about seven percent of patients had heart failure alone. The overlap was greatest in preserved ejection fraction. Risk rose in steps with each added condition. In reduced ejection fraction, carrying all four conditions was linked to roughly five times the odds of dying in hospital, compared with about double in preserved ejection fraction. Among Medicare beneficiaries, post-discharge mortality roughly doubled in reduced ejection fraction but rose only modestly in preserved ejection fraction, while heart failure readmission roughly doubled across the ejection fraction spectrum. These are observational associations, so they describe prognosis rather than proving that treating each condition changes outcomes. That question is taken up by an Expert Consensus Statement in the European Journal of Heart Failure from Inciardi and colleagues [2], which argues that renin-angiotensin inhibitors, SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists and incretin-based agents offer complementary protection against heart failure, cardiovascular death and kidney progression in high-risk people. The authors favour early, parallel initiation of these drugs in at-risk and pre-heart failure stages, supported by structured laboratory monitoring and shared cardiology, nephrology, endocrinology and primary care pathways. This is expert consensus rather than new trial evidence, and the authors name clinical inertia, polypharmacy, cost and unequal access as the main barriers.

One incretin agent got a major safety readout this week in The Lancet. Klein and colleagues report ACHIEVE-4, an open-label, event-driven trial in about 2,750 adults with type 2 diabetes, overweight or obesity, and established cardiovascular or chronic kidney disease, comparing oral orforglipron, a non-peptide GLP-1 receptor agonist, with titrated insulin glargine [3]. Over a median of two years, the four-component major adverse cardiovascular event outcome occurred in about four percent of patients on orforglipron and five percent on glargine. That met the prespecified non-inferiority margin, though it was not shown to be superior. Gastrointestinal adverse events were common, affecting about six in ten orforglipron patients versus about one in seven on insulin, and were the leading reason for stopping the drug. Severe or clinically significant hypoglycaemia fell from about one in five patients on glargine to about one in fifteen on orforglipron. Fewer deaths occurred with orforglipron, but that difference was not a formal efficacy test, and the trial establishes safety, not cardiovascular benefit. Rounding out the theme, an American College of Cardiology Scientific Statement in the Journal of the American College of Cardiology, led by Hu, reviews nutrition across cardiovascular and metabolic disease [4]. It supports a move away from single nutrients toward whole dietary patterns. The evidence it cites favours replacing saturated with unsaturated fats, more fibre and whole grains, and less sodium and fewer ultra-processed foods, especially sugar-sweetened drinks and processed meats. Mediterranean, DASH and plant-rich patterns are consistently linked to lower cardiovascular risk, and the statement highlights Food Is Medicine programmes and clinician education as routes into practice.

Our second theme covers decisions at the edges of the care pathway, from the ambulance to the operating room to the transplant clinic. In Heart, Sagel and colleagues report PreHEART 3, a pragmatic Dutch randomised trial of 5,170 adults seen by emergency medical services for undifferentiated chest pain [5]. Conveyance decisions guided by the prehospital PreHEART score were non-inferior to usual care for serious adverse events at three days, and there were no deaths within three days among the 1,526 patients left at home. Score-guided care raised the share of patients not transported by about ten percentage points, to roughly 35 percent, trimmed emergency presentations over 30 days by about an eighth, and saved around 345 euros per patient. Women in the score-guided arm had more acute coronary syndrome diagnosed and more angiography, but that signal did not survive correction for multiple testing, so it is hypothesis-generating. The trial was conducted in one national system, and how it transfers to other emergency services is still untested. In JAMA Cardiology, Dalén and colleagues report seven-year outcomes from SWEDEGRAFT, which randomised 900 patients undergoing isolated bypass surgery in Sweden and Denmark to no-touch or conventional saphenous vein harvesting [6]. Death, myocardial infarction or repeat revascularization occurred in about a fifth of patients in each arm, with no meaningful difference and no difference in any component. Combined with the excess of leg wound complications reported earlier, the authors conclude that a net clinical benefit of routine no-touch harvesting has not been established. In transplant, Shannon and colleagues in the European Heart Journal prospectively validated HEARTBiT, a blood transcriptomic test for moderate-to-severe acute cellular rejection, across four centres and 117 recipients [7]. Discrimination was moderate and held steady both within the high-risk first 60 days and later. Tuned for sensitivity, the test missed at most one rejection episode, at the cost of specificity of roughly one half, which makes it a rule-out tool rather than a diagnostic one. Scores also tended to rise weeks before biopsy confirmed rejection. The authors estimate it could safely spare more than half of surveillance biopsies, though this is a modest-sized diagnostic study and the later-period threshold was exploratory.

Our final theme is guidance that shapes daily practice. The Journal of the American College of Cardiology published the 2026 multisociety guideline on perioperative cardiovascular management for noncardiac surgery, led by Thompson [8]. It formally supersedes the 2014 guideline and updates recommendations on evaluation, pharmacological therapy, monitoring and devices for adults undergoing noncardiac surgery. The abstract does not detail individual recommendations, so the specifics need to be read in the full document. In Circulation, an American Heart Association Scientific Statement led by Rudd addresses antithrombotic undertreatment, meaning omission, nonadherence and underdosing, in atrial fibrillation, venous thromboembolism and peripheral artery disease [9]. It summarises evidence linking undertreatment to more ischaemic stroke, embolism, recurrent thrombosis and death. It attributes much of the gap to overestimated bleeding risk and to inequities in access, and it puts forward antithrombotic stewardship as the structured response. And in the European Heart Journal, Moharem-Elgamal and colleagues provide a practical guide to cardiac magnetic resonance for general cardiologists [10]. It covers indications and prognostic value across ischaemic disease, cardiomyopathies, valve disease, aortopathy, masses, pericardial disease and adult congenital disease, along with scanning patients who have implanted devices.

If you only have time for one paper this week, make it ACHIEVE-4 in The Lancet [3]. It is the first cardiovascular outcomes evidence for an oral non-peptide GLP-1 receptor agonist, and it settles the safety question while leaving cardiovascular benefit open.

Here is what this week's evidence adds up to in Cardiology. First, most patients hospitalized with heart failure carry multiple overlapping metabolic, renal and vascular conditions, and observational registry data show risk climbing with each one, steepest in reduced ejection fraction. Consensus now favours early combined preventive therapy, but outcome trials of that strategy are still needed. Second, oral orforglipron is non-inferior to insulin for cardiovascular safety in high-risk type 2 diabetes, with less hypoglycaemia but frequent gastrointestinal effects, and benefit remains unproven. Third, a single Dutch randomised trial supports score-guided ambulance triage of chest pain as safe and cost-saving, with a possible but unconfirmed signal of better detection in women. Fourth, seven-year randomised data do not show that no-touch vein harvesting improves hard outcomes after bypass surgery. Fifth, a blood transcriptomic test shows promise for ruling out early rejection after heart transplantation, though validation so far comes from a modest cohort. The new perioperative guideline now replaces the 2014 version as the reference document.

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.